Inicio Zine News Oncternal Therapeutics Announces Opening of Randomized Phase 2 Study of Cirmtuzumab in...

Oncternal Therapeutics Announces Opening of Randomized Phase 2 Study of Cirmtuzumab in Combination with Ibrutinib

5
0
Interim objective response rate of 100% in evaluable patients with CLL receiving the recommended dosing regimen supports opening Phase 2
Interim objective response rate of 100% in evaluable patients with CLL receiving the recommended dosing regimen supports opening Phase 2